StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Neurocrine Bio. (NBIX) PT Raised to $200 at Canaccord
April 6, 2026 2:41 PM
Canaccord analyst Sumant Kulkarni raised ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst PT Change
Next Articles
Neurocrine Bio. (NBIX) PT Raised to $220 at Oppenheimer on SLNO deal
April 6, 2026 1:59 PM
Baird on Neurocrine Bio's Soleno deal: Incrementally positive on acquisition
April 6, 2026 1:10 PM
UBS Reiterates Buy Rating on Neurocrine Bio. (NBIX) Following Reports of Soleno Acquisition
April 6, 2026 9:35 AM
Form 8-K NEUROCRINE BIOSCIENCES For: Apr 05
April 6, 2026 7:35 AM
Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout
April 6, 2026 7:07 AM
Neurocrine to acquire Soleno Therapeutics for $2.9 billion in cash deal
April 6, 2026 7:01 AM
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
April 6, 2026 7:00 AM
Neurocrine Biosciences nearing over $2.5B deal for Soleno Therapeutics
April 6, 2026 5:53 AM
